Freeline Initiates Dosing of Second Cohort in B-LIEVE Dose Confirmation Trial of FLT180a in Hemophilia B
June 14, 2022 07:00 ET
|
Freeline Therapeutics
Initial cohort one data suggest predictable and sustained Factor IX normalization, supporting additional dosing at the same low dose with the same optimized, prophylactic immune management regimen ...
Freeline Announces May 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 03, 2022 16:02 ET
|
Freeline Therapeutics
LONDON, June 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on May 31, 2022, the Company granted its newly hired Chief Financial Officer, Paul...
Freeline Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
June 03, 2022 16:01 ET
|
Freeline Therapeutics
LONDON, June 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today disclosed the receipt of a notice (the “Notice”) on May 31, 2022 from...
EHang Reports First Quarter 2022 Unaudited Financial Results
May 31, 2022 06:34 ET
|
EHang Holdings Limited
Special Conditions for EH216-S Type Certification Formally Adopted by CAACNewly-Appointed Chief Operating Officer to Oversee Sales and OperationsIncreasing Number of Pre-Orders from More Asian Markets...
EHang and C.P. Group Form Strategic Partnership to Introduce Autonomous Aerial Vehicles to Thailand for Urban Air Mobility
May 27, 2022 07:27 ET
|
EHang Holdings Limited
GUANGZHOU, China, May 27, 2022 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading autonomous aerial vehicle (“AAV”) technology platform company,...
Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics
May 17, 2022 08:00 ET
|
Ultragenyx Pharmaceutical Inc.
ABO-102 / UX111 is being evaluated in ongoing pivotal Transpher A trial in patients with MPS IIIA Interim data featured in encore oral presentation at American Society of Gene & Cell Therapy...
Shape Therapeutics to Present Data Highlighting Advances in Its AI-Driven RNA Technology Platforms at the 2022 ASGCT Annual Meeting
May 12, 2022 08:00 ET
|
Shape Therapeutics, Inc.
SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Shape Therapeutics® Inc. the RNA technology company advancing programmable medicine, today announced new data from its RNAfix®, RNAskipTM and AAVidTM...
Freeline Reports First Quarter 2022 Financial Results and Business Highlights
May 10, 2022 16:01 ET
|
Freeline Therapeutics
Phase 1/2 clinical programs in Hemophilia B, Gaucher disease and Fabry disease on track to deliver 2022 milestones Recent appointment of new Chief Financial Officer further strengthens leadership...
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2022 16:01 ET
|
Freeline Therapeutics
LONDON, May 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that on April 29, 2022, the Company granted five newly hired...
Freeline To Present at the 25th Annual Meeting of the American Society of Gene and Cell Therapy
May 02, 2022 17:10 ET
|
Freeline Therapeutics
LONDON, May 02, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced the upcoming presentation of five posters at the 25th Annual...